G

Greenfern Industries Ltd
NZX:GFI

Watchlist Manager
Greenfern Industries Ltd
NZX:GFI
Watchlist
Price: 0.023 NZD Market Closed
Market Cap: NZ$2.9m

Relative Value

GFI doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of GFI.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GFI Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

GFI Competitors Multiples
Greenfern Industries Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NZ
Greenfern Industries Ltd
NZX:GFI
2.7m NZD 6 -1.7 -2.4 -2.4
US
Eli Lilly and Co
NYSE:LLY
987.6B USD 16.6 53.6 36 38.6
US
Johnson & Johnson
NYSE:JNJ
565.6B USD 6 21 14.6 17.9
CH
Roche Holding AG
SIX:ROG
280.6B CHF 4.6 30 12.7 14.8
UK
AstraZeneca PLC
LSE:AZN
214.3B GBP 5.1 31.7 15.1 22.2
CH
Novartis AG
SIX:NOVN
223.4B CHF 5.2 20.2 12.7 16.4
US
Merck & Co Inc
NYSE:MRK
291.6B USD 4.5 15.1 10.7 12.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.9 11 12.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
146.4B USD 2.3 14.9 7.6 10.3
FR
Sanofi SA
PAR:SAN
97.3B EUR 1.7 8.2 7.7 7.7
P/E Multiple
Earnings Growth PEG
NZ
G
Greenfern Industries Ltd
NZX:GFI
Average P/E: 23.4
Negative Multiple: -1.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.6
54%
1
US
Johnson & Johnson
NYSE:JNJ
21
6%
3.5
CH
Roche Holding AG
SIX:ROG
30
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
38%
0.8
CH
Novartis AG
SIX:NOVN
20.2
17%
1.2
US
Merck & Co Inc
NYSE:MRK
15.1
14%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
2%
8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
FR
Sanofi SA
PAR:SAN
8.2
1%
8.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NZ
G
Greenfern Industries Ltd
NZX:GFI
Average EV/EBITDA: 46.1
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.6
2%
7.3
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
CH
Novartis AG
SIX:NOVN
12.7
6%
2.1
US
Merck & Co Inc
NYSE:MRK
10.7
6%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
7.7
8%
1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NZ
G
Greenfern Industries Ltd
NZX:GFI
Average EV/EBIT: 98.9
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.6
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.9
6%
3
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
22.2
23%
1
CH
Novartis AG
SIX:NOVN
16.4
12%
1.4
US
Merck & Co Inc
NYSE:MRK
12.7
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5
FR
Sanofi SA
PAR:SAN
7.7
6%
1.3